Abstract:Osteoclasts are myeloid lineage-derived bone-resorbing cells of hematopoietic origin. They differentiate from myeloid precursors through a complex regulation process where the differentiation of preosteoclasts is followed by intercellular fusion to generate large multinucleated cells. Under physiological conditions, osteoclastogenesis is primarily directed by interactions between CSF-1R and macrophage colony-stimulating factor (M-CSF, CSF-1), receptor activator of nuclear factor NF-κB (RANK) and RANK ligand (RANKL), as well as adhesion receptors (e.g., integrins) and their ligands. Osteoclasts play a central role in physiological and pathological bone resorption and are also required for excessive bone loss during osteoporosis, inflammatory bone and joint diseases (such as rheumatoid arthritis) and cancer cell-induced osteolysis. Due to the major role of osteoclasts in these diseases the better understanding of their intracellular signaling pathways can lead to the identification of potential novel therapeutic targets. Non-receptor tyrosine kinases and lipid kinases play major roles in osteoclasts and small-molecule kinase inhibitors are emerging new therapeutics in diseases with pathological bone loss. During the last few years, we and others have shown that certain lipid (such as phosphoinositide 3-kinases PI3Kβ and PI3Kδ) and tyrosine (Src−family and Syk) kinases play a critical role in osteoclast differentiation and function in humans and mice. Some of these signaling pathways shows similarity to immunoreceptor-like receptor signaling and involves important other enzymes (e.g., PLCγ2) and adapter proteins (such as the ITAM−bearing adapters DAP12 and the Fc-receptor γ-chain). Here, we review recently identified osteoclast signaling pathways and their role in osteoclast differentiation and function as well as pathological bone loss associated with osteolytic tumors of the bone. A better understanding of osteoclast signaling may facilitate the design of novel and more efficient therapies for pathological bone resorption and osteolytic skeletal metastasis formation.

Osteoclast differentiation by RANKL and OPG signaling pathways

Role of OPG/RANKL/RANK system during alveolar bone resorption and remodeling

Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation

The molecular understanding of osteoclast differentiation

Transforming Growth Factor β Affects Osteoclast Differentiation via Direct and Indirect Actions

RANKL-stimulated TNFα production in osteoclast precursor cells promotes osteoclastogenesis by modulating RANK signaling pathways

Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases

RANKL as the master regulator of osteoclast differentiation

RANKL biology: bone metabolism, the immune system, and beyond

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Tumor Necrosis Factor α Stimulates Osteoclast Differentiation by a Mechanism Independent of the Odf/Rankl–Rank Interaction

Osteoclast Signal Transduction During Bone Metastasis Formation

Correlating Rank Ligand/Rank Binding Kinetics with Osteoclast Formation and Function

Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption

Mature Osteoclast–derived Apoptotic Bodies Promote Osteogenic Differentiation Via RANKL-mediated Reverse Signaling

Osteoclast differentiation in rheumatoid arthritis

Discovery of the RANKL/RANK/OPG system

Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption

Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption

Unraveling the intricacies of osteoclast differentiation and maturation: insight into novel therapeutic strategies for bone-destructive diseases

Mechanisms of RANKL delivery to the osteoclast precursor cell surface